ClinicalTrials.Veeva

Menu

A Trial Of Azithromycin SR For The Treatment Of Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis

Pfizer logo

Pfizer

Status and phase

Completed
Phase 3

Conditions

Upper Respiratory Tract Infection

Treatments

Drug: Azithromycin SR

Study type

Interventional

Funder types

Industry

Identifiers

NCT00393835
A0661176

Details and patient eligibility

About

To evaluate the clinical efficacy and safety in patients with Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis receiving a dose of 2 g of azithromycin in the SR formulation.

Enrollment

99 patients

Sex

All

Ages

16 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients who were diagnosed Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis

Exclusion criteria

  • Severe underlying disease; patients in which drug clinical evaluation is difficult because of confounding diseases.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

5

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems